Key result
High cardiovascular autonomic neuropathy prevalence in schizophrenia makes testing feasible for early CVD detection.
Why the study?
Patients with schizophrenia have elevated rates of metabolic syndrome and diabetes, yet the occurrence of cardiovascular autonomic neuropathy has not been investigated in this population.
Cross-Sectional
p-value: p=<.0001
Cardiovascular autonomic neuropathy is highly prevalent in patients with schizophrenia, and testing for it is feasible as a potential tool for detecting early stages of cardiovascular disease.
May support autonomic testing in schizophrenia care; leaves open outcome benefits.
BACKGROUND: Cardiovascular autonomic neuropathy (CAN) is an independent predictor of cardiovascular disease (CVD) in patients with diabetes as well as in patients with pre-diabetes and metabolic syndrome. Patients with schizophrenia have an increased rate of metabolic syndrome, pre-diabetes and diabetes as compared to the general population. Despite of this, occurrence CAN has not been investigated in patient with schizophrenia. Therefore, the aims of this study were (1) to evaluate the feasibility testing for CAN with a new clinical tool and (2) report the prevalence of early and manifest CAN in patients with schizophrenia. METHODS AND RESULTS: <.0001). CONCLUSION: CAN is highly prevalent in patients with schizophrenia. Testing for CAN is feasible and might be a new clinically tool for detecting early stages of CVD in patients with schizophrenia.
No takes yet. Share an insight, caveat, or question.
Omar et al. (2021) conducted a cross-sectional in Schizophrenia. Cardiovascular autonomic neuropathy (CAN) testing was evaluated on Prevalence of early and manifest CAN (p=<.0001). Cardiovascular autonomic neuropathy is highly prevalent in patients with schizophrenia, and testing for it is feasible for detecting early stages of cardiovascular disease (P<.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: